Vernalis PLC Rule 2.9 Announcement (6206R)
June 15 2018 - 11:07AM
UK Regulatory
TIDMVER
RNS Number : 6206R
Vernalis PLC
15 June 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF THAT JURISDICTION.
15 June 2018
Vernalis plc ("Vernalis", the "Company", or the "Group")
Rule 2.9 Announcement
In accordance with Rule 2.9 of the City Code on Takeovers and
Mergers, Vernalis confirms that as at the date of this
announcement, it has 526,986,000 ordinary shares of one pence each
in issue and admitted to trading on the AIM market of the London
Stock Exchange. There are no shares held in treasury. Accordingly,
the total number of voting rights in Vernalis is 526,986,000. The
International Securities Identification Number ("ISIN") for the
Company's ordinary shares is GB00B3Y5L754.
Vernalis has a Sponsored Level 1 American Depositary Receipt
("ADR") facility in the United States with ISIN US92431M2061, with
each ADR representing two Vernalis ordinary shares of one pence
each in the issued share capital of the Company. The Company's ADRs
are traded on the US over-the-counter market under the symbol
'VNLPY'.
Enquiries:
Vernalis plc: +44 (0) 118 938 0015
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Canaccord plc (Nominated Adviser and Joint
Broker): +44 (0) 20 7523 8000
Henry Fitzgerald-O'Connor
Emma Gabriel
FTI Consulting (Financial Communications): +44 (0) 20 3727 1000
Ben Atwell
Simon Conway
Stephanie Cuthbert
Evercore (Financial Adviser): +44 (0) 20 7653 6000
Julian Oakley
Alan Beirne
Notes to Editors
Vernalis is a revenue generating, pharmaceutical company with
significant expertise in drug development. The Group has two
approved products: Moxatag(R) , a once-daily formulation of the
antibiotic, amoxicillin, indicated for the treatment of tonsillitis
and/or pharyngitis secondary to Streptococcus pyogenes in adults
and pediatric patients 12 years and older; and frovatriptan for the
acute treatment of migraine. Vernalis has also nine programmes in
its NCE development pipeline in addition to significant expertise
in fragment and structure based drug discovery which it leverages
to enter into collaborations with larger pharmaceutical companies.
The Company's technologies, capabilities and products have been
endorsed over the last five years by collaborations with leading
pharmaceutical companies, including Asahi Kasei Pharma, Biogen
Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini,
Novartis and Servier.
For further information about Vernalis, please visit
www.vernalis.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RTTSFLFMIFASESM
(END) Dow Jones Newswires
June 15, 2018 12:07 ET (16:07 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Apr 2024 to May 2024
Vernalis (LSE:VER)
Historical Stock Chart
From May 2023 to May 2024